-+ 0.00%
-+ 0.00%
-+ 0.00%

Natera highlights Prospera evidence from ProTECT, DEFINE-HT studies at ISHLT 2026

PUBT·04/22/2026 13:01:17
Listen to the news
Natera highlights Prospera evidence from ProTECT, DEFINE-HT studies at ISHLT 2026
  • Natera disclosed new clinical evidence supporting its Prospera donor-derived cell-free DNA test in heart and lung transplant monitoring, slated for presentation at ISHLT 2026 across 17 abstracts, including six oral sessions.
  • Heart-transplant studies indicated Prospera trends helped flag patients at higher risk for broad adverse outcomes, with results described as outperforming biopsy in identifying several complications.
  • Real-world findings from ProTECT showed Prospera results frequently influenced clinician actions on immunosuppression management or biopsy decisions, signaling utility beyond acute rejection detection.
  • Lung-transplant abstracts linked Prospera signals to earlier recognition of infection, chronic allograft dysfunction, or other graft injury, including cases not detected by biopsy.
  • Additional data suggested Prospera levels fell following anti-reflux surgery, supporting use as a treatment-response biomarker for lung allograft injury tied to reflux.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604220900BIZWIRE_USPR_____20260422_BW144265) on April 22, 2026, and is solely responsible for the information contained therein.